Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 219
- Registration Number
- NCT01559116
- Locations
- π§πͺ
1237.20.32201 Boehringer Ingelheim Investigational Site, Gent, Belgium
π³π±1237.20.31204 Boehringer Ingelheim Investigational Site, Hengelo, Netherlands
ππΊ1237.20.36201 Boehringer Ingelheim Investigational Site, Szarvas, Hungary
Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BI 1021958Drug: Placebo to BI 1021958
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 66
- Registration Number
- NCT01541488
- Locations
- π©πͺ
1310.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
First in Man Trial of BI 113608
- Conditions
- Healthy
- Interventions
- Drug: BI 113608Drug: Placebo
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT01540825
- Locations
- π©πͺ
Boehringer Ingelheim Investigational Site, Mannheim, Germany
Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin
- Conditions
- Healthy
- Interventions
- Drug: linagliptin/metformin(high dose)Drug: Linagliptin/metformin(low dose)
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01540487
- Locations
- π¨π³
1288.5.86001 Boehringer Ingelheim Investigational Site, Beijing, China
Japan Long-term Safety for Tiotropium Plus Olodaterol
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 122
- Registration Number
- NCT01536262
- Locations
- π―π΅
1237.22.81028 Boehringer Ingelheim Investigational Site, Koriyama, Fukushima, Japan
π―π΅1237.22.81019 Boehringer Ingelheim Investigational Site, Koto-ku,Tokyo, Japan
π―π΅1237.22.81010 Boehringer Ingelheim Investigational Site, Takatsuki, Osaka, Japan
Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BI 207127
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT01535638
- Locations
- π©πͺ
1241.26.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 295
- Registration Number
- NCT01533922
- Locations
- πΊπΈ
1237.13.01307 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
πΊπΈ1237.13.01305 Boehringer Ingelheim Investigational Site, Easley, South Carolina, United States
π¦πΉ1237.13.43303 Boehringer Ingelheim Investigational Site, Linz, Austria
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 291
- Registration Number
- NCT01533935
- Locations
- π¨π¦
1237.14.11404 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
π¦πΉ1237.14.43402 Boehringer Ingelheim Investigational Site, Grieskirchen, Austria
π¦πΉ1237.14.43401 Boehringer Ingelheim Investigational Site, Neumarkt am Wallersee, Austria
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT01528735
- Locations
- π―π΅
1241.25.002 Boehringer Ingelheim Investigational Site, Kofu, Yamanashi, Japan
π―π΅1241.25.001 Boehringer Ingelheim Investigational Site, Omura, Nagasaki, Japan
π―π΅1241.25.005 Boehringer Ingelheim Investigational Site, Kurashiki, Okayama, Japan
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: tiotropium + olodaterol (high dose)Device: Respimat inhalerDrug: tiotropium+olodaterol (low dose)Drug: placebo to tiotropium+olodaterol
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 404
- Registration Number
- NCT01525615
- Locations
- πΊπΈ
1237.15.01503 Boehringer Ingelheim Investigational Site, Torrance, California, United States
πΊπΈ1237.15.01506 Boehringer Ingelheim Investigational Site, Springfield, Illinois, United States
πΊπΈ1237.15.01507 Boehringer Ingelheim Investigational Site, Iowa City, Iowa, United States